Catalyst Pharmaceuticals
Trade Catalyst Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E.
CPRX Key Statistics
Stock Snapshot
Catalyst Pharmaceuticals(CPRX) stock is priced at $21.39, giving the company a market capitalization of 2.63B. It carries a P/E multiple of 12.48.
On 2025-11-08, Catalyst Pharmaceuticals(CPRX) stock traded between a low of $20.68 and a high of $22.19. Shares are currently priced at $21.39, which is +3.4% above the low and -3.6% below the high.
Catalyst Pharmaceuticals(CPRX) shares are trading with a volume of 1.93M, against a daily average of 1.48M.
During the past year, Catalyst Pharmaceuticals(CPRX) stock moved between $19.05 at its lowest and $26.58 at its peak.
During the past year, Catalyst Pharmaceuticals(CPRX) stock moved between $19.05 at its lowest and $26.58 at its peak.
CPRX News
Catalyst Pharmaceutical Partners ((CPRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Meet Your ETF AI Analyst Discover how TipR...
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Catalyst Pharma, with a price target of $35.00. Meet Your ETF AI Analyst...
Earnings Call Insights Catalyst raises 2025 revenue guidance to $565M–$585M while launching $200M share buyback program Nov. 06, 2025 8:36 PM ET Catalyst Pharma...
Analyst ratings
100%
of 7 ratingsMore CPRX News
Catalyst Pharmaceuticals recently reported its third quarter 2025 financial results, posting revenue of US$148.39 million and net income of US$52.78 million, bo...
(RTTNews) - Catalyst Pharmaceuticals, Inc. (CPRX) released earnings for its third quarter that Increased from the same period last year and beat the Street esti...
Reports Q3 revenue $148.39M, consensus $136.8M. “Throughout 2025, we have continued to execute on our commercial growth initiatives to drive adoption of FIRDAPS...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Catalyst Pharmaceuticals (CPRX) shares edged modestly higher this week, gaining just over 1% over the past month. Investors appear to be taking a measured appro...